Events

Upcoming Events

TRANSCEND Cancer Initiative Monthly Meeting Series

TRANSCEND Cancer Initiative (TCI) hosts a monthly meeting on the last Friday of the month from 2:30-3:30 p.m. (CST). Meetings will be held virtual on zoom. Please note the schedule is subject to change. To join our meeting series, please email TranscendCancerInitiative@mdanderson.org.

January 27, 2023

• Sun Lim, Business Development Manager at Olink Proteomics
  Olink Applications in Immunotherapies
• Seth Meyers, Senior Technical Sales Specialist, NanoString Technologies
  Spatial-omics Revolution: Innovation Roadmap and Key Applications
• Allison May, M.D., Fellow, Department of Urology, University of Michigan
  Spatial molecular imaging to profile the epithelial to mesenchymal transition and immune crosstalk in sarcomatoid renal
  cell carcinoma

February 24, 2023

• Andrew Futreal, Ph.D., Chair of Genomic Medicine, UT MD Anderson Cancer Center 
• Elizabeth Burton, M.B.A., Executive Director of STRIDE, Genomic Medicine, UT MD Anderson Cancer Center

March 31, 2023

• Speakers are TBA

Spring TRANSCEND Cancer Initiative Symposium

April 21, 2023

• Agenda to follow

Past Events

TRANSCEND Cancer Initiative Monthly Meeting Series

Watch recordings of past seminars on the TCI Teams page

December 2, 2022

• Nathaniel Deboever, M.D., Rotating Resident in Research, TCI Fellow, Department of Thoracic and Cardiovascular Surgery, UT MD Anderson Cancer Center
  Multiplatform analysis of the microbiome and its associations in resectable non-small cell lung cancer managed with neoadjuvant therapy
• Yongwoo David Seo, M.D., Fellow, TCI Fellow, Department of Surgical Oncology, UT MD Anderson Cancer Center
  Cancer testis antigen and interleukin expression correlates with survival in small bowel neuroendocrine tumors

October 21, 2022

• Nicholas Navin, Ph.D., Department Chair of Systems Biology; Professor, Department of Genetics; Director of the CPRIT Single Cell Genomic Center (Single Cell Core); and the Co-Director of the Advanced Technology Genomics Core (ATGC), UT MD Anderson Cancer Center
  Decoding premalignant cancer progression with single cell genomics

September 30, 2022

• Sammy Ferri-Borgogno, Ph.D., Instructor, Department of Gynecologic Oncology and Reproductive Medicine, UT MD Anderson Cancer Center
  Long- term ovarian cancer survivors: spatial transcriptomics depict ligand receptor crosstalk heterogeneity at the tumor stroma interface
  
• Cara Haymaker, Ph.D., Director of ORION core, Assistant Professor and Luisa Maren Solis Soto, Ph.D., Assistant Professor, Department of Translational Molecular Pathology, UT MD Anderson Cancer Center
  TMP-IL: Applying digital spatial profiling techniques to translating clinical trials
  

August 19, 2022

• Eduardo Vilar-Sanchez, M.D., Ph.D., Associate Professor, Department of Clinical Cancer Prevention, UT MD Anderson Cancer Center
  Pre-Cancer Atlas and Colorectal Pre-Cancer Collaborative Studies
• Melinda S. Yates, Ph.D., Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, UT MD Anderson Cancer Center
  Role of Immune Response in Endometrial Pre-Malignant Biology and Cancer Prevention

July 8, 2022

• Samuel Cass, M.D., Rotating Resident-Research, Department of Surgical Oncology, UT MD Anderson Cancer Center
  Dietary Intervention: An Emerging Strategy for Microbiome and Immune Modulation
• Elise Nassif, M.D., Postdoctoral Fellow, Department of Surgical Oncology, UT MD Anderson Cancer Center
  B-Cell Receptors: from Biomarkers to Therapeutics

May 19, 2022

• Christof Straub, Ph.D., Regional Account Manager at NanoString Technologies, Inc.
  Discussion of GeoMx® Digital Spatial Profiler and applications that deal with tissue heterogeneity in the context of TME
• Alexander J. Lazar, M.D., Ph.D., Professor, Department of Pathology, MD Anderson Cancer Center
  Discussion of the pathologic considerations when performing spatial transcriptomics

2022 Fall TRANSCEND Cancer Initiative Symposium

October 7, 2022

Keynote presentations by:

• Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery, National Cancer Institute - Lymphocytes as a “Living Drug” for the Treatment of Cancer.
• Stephanie L. Goff, M.D., Associate Research Physician of Surgery, National Cancer Institute - Expanding TIL beyond melanoma: Lessons learned

Session I: Transforming the Field Through Surgeon Led Trials and Translational Research

• Presentations by Amir A. Jazaeri, M.D.; Samuel Cass, M.D.; Brenda Melendez, Ph.D.; Raymond Traweek, M.D.; and Golnaz Morad, Ph.D.

Session II: Minimal Residual Disease and Adoptive Cell Therapy

• Presentations by Scott Kopetz, M.D., Ph.D., F.A.C.P.; Neil D. Gross, M.D., F.A.C.S.; Travis T. Sims, M.D.; Veena Vuttaradhi. Ph.D.; and Yongwoo    David Seo, M.D.

2022 Spring TRANSCEND Cancer Initiative Symposium

April 29, 2022

Session I: Advancing cancer care through neoadjuvant approaches and targeting minimal residual disease in solid tumors

• Presentations by Amir Jazaeri, M.D.; Emily Keung, M.D.; Shannon Westin, M.D., MPH; Brenda Melendez, Ph.D.; Manoj Chelvanambi, Ph.D.; Sharada Mokkapati, Ph.D.; and Yasmine Hoballah, M.S.

Session II: Advancing cancer care through translational research and reverse translation incorporating preclinical models

• Presentations by Michael White, M.D., M.S.; Elizabeth M. Park, Ph.D.; Chi-Lam Au-Yeung, Ph.D.; Timothy P. DiPieri, M.D.; and Veena Kochat, Ph.D.
• Keynote: Padmanee Sharma, M.D. Ph.D. – Transforming cancer care with immunotherapy – vision and partnership with the Allison Institute